Patents by Inventor Lore Mariën
Lore Mariën has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11597763Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.Type: GrantFiled: May 2, 2017Date of Patent: March 7, 2023Assignee: Tetragenetics, Inc.Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini, Alka Agrawal
-
Publication number: 20210324061Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: November 12, 2020Publication date: October 21, 2021Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Patent number: 10875914Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: May 10, 2019Date of Patent: December 29, 2020Assignees: argenx BVBA, Université Catholique de LouvainInventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stëphanie Liénart, Sophie Lucas, Pierre Coulie
-
Patent number: 10793627Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: November 27, 2019Date of Patent: October 6, 2020Assignees: argenx BVBA, Université Catholique de LouvainInventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20200095311Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20190375832Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: May 10, 2019Publication date: December 12, 2019Inventors: Sebastian van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Patent number: 10479829Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: GrantFiled: May 11, 2018Date of Patent: November 19, 2019Assignees: argenx BVBA, Université Catholique de LouvianInventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Gitte De Boeck, Stéphanie Liénart, Sophie Lucas, Pierre Coulie
-
Publication number: 20190144538Abstract: Anti-Kv1.3 antibodies (mAbs), particularly mAbs that specifically bind to Kv1.3 with high affinity and/or inhibit Kv1.3 function, are disclosed. The amino acid sequences of the CDRs of the light chains and the heavy chains, as well as consensus sequences for these CDRs, of these anti-Kv1.3 mAbs are provided. Additionally, canonical structures for CDRs in the VH and VL regions of anti-Kv1.3 antibodies are provided. The disclosure also provides nucleic acid molecules encoding the anti-Kv1.3 mAbs, expression vectors, host cells, methods for making the anti-Kv1.3 mAbs, and methods for expressing the anti-Kv1.3 mAbs. Finally, methods of using the anti-Kv1.3 mAbs as therapeutics, such as for preventing or treating an autoimmune disorder, are disclosed.Type: ApplicationFiled: May 2, 2017Publication date: May 16, 2019Applicant: Tetragenetics, Inc.Inventors: Paul A. Colussi, Janna Bednenko, Yelena Bisharyan, Ashot Papoyan, Joanna Cardarelli, Theodore G. Clark, Douglas Kahn, Lore Mariën, Bas Van Der Woning, Hans De Haard, William D. Harriman, Ellen J. Collarini
-
Publication number: 20180327487Abstract: The present invention relates to antibodies and antigen binding fragments thereof, which bind to a complex of GARP and TGF-?1, particularly a complex of human GARP and human TGF-?1. These antibodies and antigen binding fragments exhibit a combination of advantageous properties including high affinity antigen binding and the ability to inhibit the release of active TGF-? from regulatory T cells. The antibodies and antigen binding fragments of the present invention are relatively resistant to deamidation, isomerization and oxidation, such that they display improved stability.Type: ApplicationFiled: May 11, 2018Publication date: November 15, 2018Inventors: Sebastian Van der Woning, Filip Borgions, Torsten Dreier, Lore Mariën, Federica Linty, Gitte De Boeck, Hans De Haard, Stéphanie Liénart, Sophie Lucas, Pierre Coulie, Michael Saunders